Actoplus Met® (pioglitazone and metformin) is approved for the treatment of type 2 diabetes (also called noninsulin-dependent diabetes or adult-onset diabetes). It is a combination medicine that is proven to lower blood sugar levels. This product comes in tablet form and is generally taken once or twice a day.
But how does the medication lower blood sugar? The answer lies in the effects of the active ingredients in Actoplus Met. The first one, pioglitazone, helps improve insulin sensitivity. The second ingredient, metformin, decreases both the amount of sugar the body produces and how much it absorbs from the diet, and also helps the body respond better to its natural insulin. These effects combined cause blood sugar to decrease.
In rare cases, Actoplus Met can lower blood sugar levels too much. Signs of this include extreme hunger, dizziness, and sweating, among other things. If this happens, contact your healthcare provider for advice on how to treat it.
(Click Actoplus Met to learn more about this diabetes medication, including exactly how it works, side effects to watch out for, what to do in cases of overdose, and general dosing guidelines.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed January 18, 2007.
Mylan, Inc. Mylan announces first-to-file opportunity settlement agreements for Actoplus Met(R) and Actos(R) (3/16/2010). Mylan Web site. Available at: http://investor.mylan.com/releasedetail.cfm?ReleaseID=452248. Accessed April 1, 2010.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click